April 26, 2022 4:47pm

As April’s sell-off continues; have we found a supportable bottom – NO. The issue where is the risk reward!

The Biostage (BSTG) Chronicles: (BSTG -$0.30), <was -$0.50> as 25,325 shares trade (from whom – Beijing, China ??): Question has BSTG filed its FDA annual report re its 3-year-old IND to initiate a clinical trial and its “particulars” – it’s a material fact.

Pre-open indications: 2 HITs, 1 MISS and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.


The Dow closed DOWN -809.28 points (-2.38%); the S&P closed DOWN -120.92 points (-2.81%) while the Nasdaq closed DOWN -514.11 points (-3.95%)



U.S. stocks fell sharply on Tuesday with shares selling off into the close, as investors dumped shares on fears of an economic slowdown.

For April, the S&P 500 is off 7.8%, the Nasdaq is down 12.2% and the Dow is down 4.2%.


52-week low:

  • XBI at $78.36
  • Beam Therapeutics (BEAM) at $41.03,
  • Caribou Biosciences (CRBU) at $7.56
  • Sangamo Therapeutics (SGMO) at $4.56,
  • Applied Genetic Technologies (AGTC) at $0.95,
  • bluebird bio (BLUE) at $3.81,
  • AVROBIO (AVRO) at $0.98
  • Homology Medicine (FIXX) at $1.65,


RegMed Investors’ (RMi) pre-open: “ride the fence” … https://www.regmedinvestors.com/articles/12405


RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Tuesday opened negative at 3 up/31 downs and 1 flat, stayed negative at the mid-day at 0/35, ending again with a negative close of 0/35,
  • Monday opened negative at 12 up/20 downs and 3 flats, flipped positive at 10:30 a.m. at 24/10 and 1 flat, the mid-day continued positive at 10/24 and 1 flat, ending with a positive close of 27/7 and 1 flat,


Pre-open Indications: 2 HITs < Intellia Therapeutics (NTLA -$3.74), CRISPR Therapeutics (CRSP -$4.47), Editas Medicine (EDIT -$1.03)> 1 MISS <Caribou Biosciences (CRBU -$0.39) > and 1 Pimp/Pump/Promote < Biostage (BSTG -$0.30 with 25,325 shares traded – notice the share count?>


Key Metrics:

  • Tuesday - Sector volume was LOW with 0 of the 0-upside having higher than the 3-month average volume with LOW volume of 13 of 35-downside having higher than the 3-month average volume;
  • Monday - Sector volume was LOW with 2 of the 27-upside having higher than the 3-month average volume with LOW volume of 2 of 7-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was down -3.86% and the XBI was down -5.98%
  • Monday, the IBB was up +0.93% and the XBI was up +2.23%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +6.50 points or +24.06% at 33.52
  • Monday was down -1.33 points or -4.71% at 26.88


Jumping with share pricing momentum (0 of 0):

Hammered in today’s market (15 of 35):

  • Alnylam Pharmaceuticals (ALNY -$7.07 after Monday’s -$4.93),
  • Ultragenyx (RARE -$4.92 after Monday’s +$0.60),
  • CRISPR Therapeutics (CRSP -$4.47 after Monday’s +$1.59),
  • Beam Therapeutics (BEAM -$4.06 after Monday’s +$2.09),
  • Intellia Therapeutics (NTLA -$3.74 after Monday’s +$2.93),
  • Fate Therapeutics (FATE -$3.01 after Monday’s +$0.82),
  • Ionis Pharmaceuticals (IONS -$2,22 after Monday’s +$0.61),
  • Global Blood Therapeutics (GBT -$2.09 after Monday’s +$1.50),
  • Sage Therapeutics (SAGE -$1.77),
  • Vericel VCEL -$1.73),
  • Regenxbio (RGNX -$1.25 after Monday’s -$0.17),
  • Editas Medicine (EDIT -$1.03 after Monday’s +$0.40),
  • uniQure NV (QURE -$0.92),
  • Chinook Therapeutics (KDNY -$0.69 after Monday’s +$0.38),
  • BioLife Solutions (BLFS -$0.60 after Monday’s +$1.20),


April, Q2/2022:

  • Tuesday closed negative with 0 incliners, 35 decliners
  • Monday closed positive with 27 incliners, 7 decliners and 1 flat


The BOTTOM LINE: Today was a BIG swoon as mean reversions.

It’s NOT just the cell and gene therapy sector that’s getting “zapped”

Sessions lows are the thing of the day, I believe by Biden policies

The Nasdaq was the worst performing index as it dipped nearly 4%

Small caps were also given a shellacking as the Russell 2000 fell 2.4%.

Relevance is defined, “This week may easily be a fork in the road of equities. ... Bottom-up drivers will either confirm or reject what the challenging macro backdrop has given us over the last three weeks,” MKM’s JC O’Hara said in a note. <CNBC>

State the obvious, investors are NOT in control of daily market driven sector appreciation or downward dives.

Relevant quote, “April has historically been a strong month for stocks, and has produced a positive return for the S&P 500 in 15 of the last 16 years, LPL Financial's Ryan Detrick pointed out in a note earlier this month. This month, however, markets were wrought by Russia's war in Ukraine, continued worries around the Federal Reserve's rate hiking cycle, inflationary and supply chain pressures, and fears the culmination of these headwinds may result in an economic slowdown.” <Yahoo Finance>

I try to keep it simple … I don't think we've seen the bottom yet. We haven't had that big sell off yet where we have huge volumes.

We are getting close to Q2 reporting season … yet, I can’t write away my misgivings about the daily sessions. 

Earnings’ season is upon us as Solid Biosciences (SLDB) reports 4/27 followed by Alnylam Pharmaceuticals (ALNY) reports Thursday,4/28 followed by Sage Therapeutics (SAGE) on 5/3 and AxoGen (AXGN), Ionis Pharmaceuticals (IONS), MiMedx (MDXG) and Vericel (VCEL), and Fate Therapeutics (FATE) on 5/4 so far.

Volume again was also barely there … as earnings might get even more ugly.

Don’t hold your breath after a few up sessions, algorithms are lurking under the surface of minimal sentiment

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.


Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.